Evidence map›Paper›PMID 38574700›Full record

Trial reportPsychiatry research2024

The utility of measuring daily hassles and uplifts in understanding outcomes to treatments for major depressive disorder.

Benjamin W Furman, W Edward Craighead, Helen S Mayberg, Tanja Mletzko, Charles B Nemeroff, Boadie W Dunlop

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Psychiatry research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Benjamin W FurmanEmory University School of Medicine, Atlanta, GA, USA.
W Edward CraigheadDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, USA; Department of Psychology, Emory University, Atlanta, USA.
Helen S MaybergDepartment of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, USA.
Tanja MletzkoDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, USA.
Charles B NemeroffDepartment of Psychiatry and Behavioral Sciences, Institute for Early Life Adversity Research, University of Texas at Austin Dell Medical School, Austin, TX, USA.
Boadie W DunlopDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, USA. Electronic address: bdunlop@emory.edu.
Emory University · USIcahn School of Medicine at Mount Sinai · USThe University of Texas at Austin · US

Funding

Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025008 · NCRR · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2007 to 2011
$29.0M
X LINKED NYSTAGMUS SYNDROME WITH FEATURES OF ALBINISMM01RR000039 · NCRR · EMORY UNIVERSITY · PI VACCARINO, VIOLA · 1985 to 2007
$21.3M
Metabolomic Signatures for Disease Sub-classification and Target Prioritization in AMP-ADU01AG061359 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, KASTENMULLER, GABI · 2018 to 2022
$10.0M
Special Scientific Procedures: Statistical Modeling CoreP50MH077083 · NIMH · EMORY UNIVERSITY · PI MAYBERG, HELEN S · 2006 to 2010
$9.3M
Predictors of Treatment Response Relapse and Recurrence in Major DepressionR01MH080880 · NIMH · EMORY UNIVERSITY · PI CRAIGHEAD, W. EDWARD · 2008 to 2012
$6.6M
Metabolic Networks and Pathways in Alzheimer's DiseaseR01AG046171 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F · 2014 to 2017
$4.4M
Metabolomic Signatures Predictive of Outcomes to Treatments for Major DepressionR01MH108348 · NIMH · DUKE UNIVERSITY · PI DUNLOP, BOADIE W, KADDURAH-DAOUK, RIMA F · 2016 to 2019
$2.7M
NCATS NIH HHS UL1 TR002378NCRR NIH HHS M01 RR000039NCRR NIH HHS UL1 RR025008NIA NIH HHS R01 AG046171NIA NIH HHS U01 AG061359NIMH NIH HHS P50 MH077083NIMH NIH HHS R01 MH080880NIMH NIH HHS R01 MH108348
6 · The paper itself

Abstract

Little is known about the effects of common daily experiences in patients with major depressive disorder (MDD). The Daily Hassles and Uplifts Scale (HUPS) was assessed in 142 treatment-naïve adult MDD outpatients randomized to 12 weeks of treatment with either antidepressant medication (ADM) or Cognitive Behavior Therapy (CBT). Three HUPS measures were analyzed: hassle frequency (HF), uplift frequency (UF), and the mean hassle intensity to mean uplift intensity ratio (MHI:MUI). Remission after treatment was not predicted by these baseline HUPS measures and did not moderate outcomes by treatment type. In contrast, HUPS measures significantly changed with treatment and were impacted by remission status. Specifically, HF and MHI:MUI decreased and UF increased from baseline to week 12, with remission leading to significantly greater decreases in HF and MHI:MUI compared to non-remission. ADM-treated patients demonstrated significant improvements on all three HUPS measures regardless of remission status. In contrast, remitters to CBT demonstrated significant improvements in HF and MHI:MUI but not UF; among CBT non-remitters the only significant change was a reduction in HF. The changes in HUPS measures are consistent with how affective biases are impacted by treatments and support the potential value of increasing attention to positive events in CBT.

Indexed as

Cognitive Behavioral TherapyMajor Depressive DisorderAdultAntidepressive AgentsHumansTreatment OutcomeAntidepressive AgentsAntidepressantDepressionPsychotherapyQuality of lifeRecurrenceRelapseRemission

Identifiers

PMID38574700
PMCPMC11015958
OpenAlexW4392948331

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.